EVALUATION OF BETA BLOCKERS USE AT A TERTIARY CARE HOSPITAL

Similar documents
DRUG UTILIZATION PATTERNS OF ANTIHYPERTENSIVES IN VARIOUS WARDS IN A TERTIARY CARE HOSPITAL IN TAMILNADU

International Journal of Advancements in Research & Technology, Volume 2, Issue 6, June-2013 ISSN

Hypertension (JNC-8)

Volume 2 Number 2 (2011)

Stable Angina Treatment Strategies and Current Practices in Lahore, Pakistan: A Cross-Sectional Analysis

Prescribing Trend of Antihypertensive Drugs in Sri Ganganagar District: A Retrospective Study

Pre-ALLHAT Drug Use. Diuretics. ß-Blockers. ACE Inhibitors. CCBs. Year. % of Treated Patients on Medication. CCBs. Beta Blockers.

Antihypertensive Drugs Prescribing Pattern in Patients Attending to Medicine Outpatient Department

Andhra Pradesh, India Corresponding Author: Dr. S. Parveen *

Prescription Pattern of Anti-Hypertensive Drugs in Adherence to JNC- 7 Guidelines

335 Full Text Available On Original Article!!! Pharmaceutical Sciences

Chapter (9) Calcium Antagonists

Use of Beta-blocker Monotherapy in Hypertension: Situation in a Local General Outpatient Clinic

Evaluation of Drug Information Service provided by Clinical Pharmacy Department based on Provider and Enquirers' Perspective

Layered Approaches to Studying Drug Responses

Heart Failure Clinician Guide JANUARY 2018

JMSCR Vol 06 Issue 05 Page May 2018

Hypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program

What in the World is Functional Medicine?

By Prof. Khaled El-Rabat

Metoprolol Succinate SelokenZOC

Heart Failure Update John Coyle, M.D.

ACP Brief Fall 2006 prioritization. Angiotensin II Receptor Blockers (ARBs) for Proteinuria, Hypertension (HTN) and Congestive Heart Failure (CHF)

First line treatment of primary hypertension

Difficult to Treat Hypertension

Hypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015

Heart Failure Clinician Guide JANUARY 2016

Prescribing Pattern of Antihypertensive Drugs in Hypertensive Patients in Tertiary Care Hospital

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension

NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT

DRUG CLASSES BETA-ADRENOCEPTOR ANTAGONISTS (BETA-BLOCKERS)

Antihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Adapted d from Federation of Health Regulatory Colleges of Ontario Template Last Updated September 18, 2017

Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary

Drug prescriptions (Pharm) Exposure (36/48 months)

Original article: A Study of prescription pattern of antihypertensive drugs in a tertiary Care teaching hospital

DRUG USE EVALUATION OF ANTIHYPERTENSIVE DRUGS IN THE TERTIARY CARE HOSPITAL

Beta-blockers: Now what? Annemarie Thompson, MD Assistant Professor of Anesthesia and Medicine Vanderbilt University Medical Center

ALLHAT. Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic

Antihypertensive drugs SUMMARY Made by: Lama Shatat

ADVANCES IN MANAGEMENT OF HYPERTENSION

STUDY OF DRUG UITLIZATION PATTERN OF ANTIHYPERTENSIVE DRUGS IN HYPERTENSIVE NEPHROPATHY IN A TERTIARY CARE TEACHING HOSPITAL, BAREILLY, U.P.

DRUG UTILIZATION EVALUATION OF ANTI-HYPERTENSIVE AGENTS IN A MEDICAL CARE HOSPITAL

Heart Failure (HF) Treatment

Chapter 10. Learning Objectives. Learning Objectives 9/11/2012. Congestive Heart Failure

National Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008

Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris

Management of Hypertension

ADVANCES IN MANAGEMENT OF HYPERTENSION

Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs

Long-Term Care Updates

The EuroHeart Failure Survey programme a survey on the quality of care among patients with heart failure in Europe

VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005

Factors Involved in Poor Control of Risk Factors

Preventing and Treating High Blood Pressure

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Managing Hypertension in 2016

DECLARATION OF CONFLICT OF INTEREST

Antihypertensive drugs: I. Thiazide and other diuretics:

Modern Management of Hypertension: Where Do We Draw the Line?

ANGINA PECTORIS. angina pectoris is a symptom of myocardial ischemia in the absence of infarction

Combination Therapy for Hypertension

Hypertension Update 2009

β adrenergic blockade, a renal perspective Prof S O McLigeyo

Hypertension. Penny Mosley MRPharmS

ABSTRACT KEYWORDS: The prevalence of hypertension varies from percentages in all

Chapter / Section / Drug

Modern Management of Hypertension

What s In the New Hypertension Guidelines?

A Study Conducted At A Tertiary Care Teaching Institute in Chennai, on The Clinical And Etiological Profile Of Patients With Acute Heart Failure.

HYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP

Int. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences

Target dose achievement of evidencebased medications in patients with heart failure with reduced ejection fraction attending a heart failure clinic

Evidence Supporting Post-MI Use of

Section 3, Lecture 2

MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk

Management of Hypertension in special groups. DR-Mohammed Salah Assistant Lecturer of Cardiology Mansoura University

Update in Hypertension

ANTI- HYPERTENSIVE AGENTS

Angina pectoris due to coronary atherosclerosis : Atenolol is indicated for the long term management of patients with angina pectoris.

Role of Pharmacoepidemiology in Drug Evaluation

Adrenergic Receptor as part of ANS

HYPERTENSION IN THE ELDERLY A BALANCED APPROACH. Barry Goldlist October 31, 2014

Dr. Vishaal Bhat. anti-adrenergic drugs

Management of High Blood Pressure in Adults

EVALUATION OF PRESCRIBING PATTERN OF ANTIHYPERTENSIVE DRUGS IN A TERTIARY CARE HOSPITAL

Treating Hypertension in Individuals with Diabetes

MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION

Evaluation of Prescribing Trends in Ambulatory Cardiac Patients above 50 Years of Age in Lahore, Pakistan

Heart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid

Therapeutic Targets and Interventions

SBP in range of 120 to 140 :no progression or regression of CAD. Sipahi et al., 2006

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Journal of Advances in Medical and Pharmaceutical Sciences. 17(1): 1-9, 2018; Article no.jamps ISSN:

Antihypertensive Trial Design ALLHAT

Should beta blockers remain first-line drugs for hypertension?

Antihypertensives. Antihypertensive Classes. RAAS Inhibitors. Renin-Angiotensin Cascade. Angiotensin Receptors. Approaches to Hypertension Treatment

Study Exposures, Outcomes:

Heart Failure 101 The Basic Principles of Diagnosis & Management

Transcription:

Page2587 Indo American Journal of Pharmaceutical Research, 2015 ISSN NO: 2231-6876 EVALUATION OF BETA BLOCKERS USE AT A TERTIARY CARE HOSPITAL Sukesh Krishna Chaitanya Loka *, Vinuthna Yashki, Alekhya Vissampally, Divya Jose Malla Reddy Institute of Pharmaceutical Sciences, Hyderabad. ARTICLE INFO Article history Received 21/04/2015 Available online 01/08/2015 Keywords DUE, Beta Blockers, Hypertension, Drug Interaction. ABSTRACT Drug Utilization Evaluation (DUE) is an ongoing, authorized and systematic quality improvement process designed to review drug use and promote appropriate drug use through interventions. Beta blockers, one of the prescribed classes of cardio vascular medications reduce morbidity and mortality in patients with cardiac disease. The present study aimed to evaluate the prescribing pattern of beta blockers use. A prospective, observational study w a s carried out in inpatients of general medicine, and surgical departments of tertiary care hospital. Structurally designed proforma was used to collect patient data such as demographics, medical history, and treatment. The data was then analyzed using Microsoft Excel and evaluated. A total of 135 patients have been identified who were prescribed with beta blockers among which females accounted for 51.1% while males for 48.8%. Average length of hospital stay was 6 days. The most common diagnoses were Hypertension (62.2%), and Diabetes mellitus (34.8%). Beta blockers were mostly prescribed among the age group 50-69 years (50.3%) and the widely prescribed was metoprolol (39.2%). The other anti hypertensive drugs concurrently prescribed with beta blockers included diuretics (51.1%). Major drug interactions were found in 9.83% only. Beta blockers most commonly prescribed include Metoprolol followed by atenolol. It is highly necessary for the clinical pharmacist to review and clinically check all prescriptions presented at the wards (check for appropriate dose, frequency, drug interactions etc.). Corresponding author Sukesh Krishna Chaitanya Loka Plot No: 2-1/28, Opp KVR towers B block Widia Colony, Cine town lane Miyapur, Hyderabad- 500049 Telangana, India. Please cite this article in press as Sukesh Krishna Chaitanya Loka et al. Evaluation of Beta blockers use at a tertiary care hospital. Indo American Journal of Pharm Research.2015:5(07). Copy right 2015 This is an Open Access article distributed under the terms of the Indo American journal of Pharmaceutical Research, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Page2588 INTRODUCTION DUE is an ongoing, systematic process designed to maintain the appropriate use and effective use of drugs. It involves a comprehensive review of patient s prescription and medication data before, during and after dispensing in order to assure appropriate therapeutic decision making and positive patient outcomes [1]. DUE is a performance improvement method that focuses on evaluating and improving drug use processes to achieve optimal patient outcomes. DUE may be applied to a drug or therapeutic class, or diagnosis [2]. Pharmacists routinely perform prospective reviews by assessing a prescription medication's dosage and its directions and reviewing patient information for possible drug interactions or duplicate therapy. Concurrent review is performed during the course of treatment and involves the ongoing monitoring of drug therapy to ensure positive patient outcomes. In retrospective DUE, patient medical charts or computerized records are screened to determine whether the drug therapy met approved criteria and aids prescribers in improving care for their patients, individually and within groups of patients, such as those with diabetes, asthma, or high blood pressure [3]. Beta b l o c k e r (-blockers, beta-adrenergic blocking agents, beta antagonists, beta adrenergic antagonists, beta-adrenoreceptor antagonists, or beta adrenergic receptor antagonists) are a class of drugs that target the beta receptor. These drugs inhibit adrenergic responses mediated through the receptor and are the most prescribed classes of cardiovascular medications. Beta blockers are registered for a wide range of indications including hypertension, angina pectoris, arrhythmias, heart failure, and as secondary prevention after MI. Long-term beta-adrenergic receptor blockade is a promising approach to the treatment of heart failure [4]. Beta blockers are effective only when they are rationally prescribed and used. These are most effective when given in combination with other anti-hypertensive medications particularly thiazide d i u r e t i c s [5]. Beta-blockers were the next class of drugs shown to save lives in CHF, when given on top of standard therapy with diuretics, ACE inhibitors, and optional digitalis glycosides. They reduce mortality in patients with cardiovascular disease, most notably after MI in the presence of CHF [6]. The present study aims to evaluate the prescribing patterns of beta blockers in a tertiary care hospital and the main objective is to control the misuse of beta blockers and promote rational drug therapy. Methodology: A prospective observational study had been conducted in the General Medicine and surgical departments of a tertiary care hospital in Hyderabad. The study had been conducted for a period of six months. All patients who were prescribed with beta blockers had been included in the study excluding pregnant and lactating women. A structurally designed data collection form was used to collect information such as demographics, medical history, lab investigations, and treatment and progress notes. The collected data was then evaluated and analyzed using Microsoft-Excel. RESULTS: A total of 135 patients have been evaluated with the use of beta blockers. GENDER DISTRIBUTION In the study population, out of 135 patients 66 were Male patients and 69 Female patients. It indicates this study is female dominated. Table 1: Gender Distribution in Study Population. GENDER NO.OF PATIENTS PERCENTAGE (%) Male 66 48.88 Female 69 51.11 Age distribution Out of 135 patients, 5 were below 30 years which are less whereas patients belonging to age group of 31 49 were 42. In case of middle age and young old age group, number of patients was found to be 68 who are more, whereas the patients in the age group 70-90 years were 20. Table 2: Age Distribution in Study Population. AGE NO.OF PATIENTS PERCENTAGE (%) <30 5 3.7 31 49 42 31.1 50 69 68 50.3 70 90 20 14.8 DURATION OF HOSPITAL STAY: The duration of hospital stay of 2 days for 8.1%, 3 days for 8.8%, 4 days for 14%, 5 days for 18.5%, 6 days for 12.5%, followed by 37.7% were admitted in the hospital for >7 days.

Page2589 Table 3: Duration of Hospital Stay in Study Population. DURATION NO.OF PATIENTS PERCENTAGE (%) 2 Days 11 8.1 3 Days 12 8.88 4 Days 19 14.07 5 Days 6 Days 25 17 18.51 12.59 >7 Days 51 37.7 REASON FOR ADMISSION: In our study, the major complaints reported include breathlessness for 42.9% of patients. Swelling of 29.6% and fever, headache, chest pain was reported in 17.7% of patients. Also other complaints reported include generalized weakness, involuntary movements and pain which comprise 29.61%. Table 4: Reason for Admission of Study Population. REASON FOR ADMISSION NO. OF PATIENTS PERCENTAGE (%) Swelling 40 29.62 Breathlessness 58 42.96 Fever, Headache 24 17.77 Chest pain 24 17.77 Generalized Weakness 9 6.66 Involuntary movements 7 5.18 Others 12 8.88 DIAGNOSIS OF STUDY POPULATION In the study population hypertensive patients were more prominent, found in 84 patients (62.2%). It is followed by diabetes (34.8%) and CHF (14.8%), whereas other diagnoses comprised 15.5%. Table 5: Diagnosis of study population. DIAGNOSIS NO.OF PATIENTS PERCENTAGE (%) HTN 84 62.22 DM 47 34.81 IHD 13 9.62 LVF 11 8.14 CHF 20 14.81 STROKE 10 7.40 CKD 13 9.62 Portal HTN, Tachycardia 7 5.18 Others 21 15.5 BETA BLOCKERS PRESCRIBED: In our study the main beta-blockers prescribed where metoprolol (39.2%), atenolol (28.1%), carvedilol (18.5%), propranolol (13.3%) and labetolol (0.7%). Table 6: Beta Blockers Prescribed in Study Population. BETA BLOCKERS PRESCRIBED NO. OF PATIENTS PERCENTAGE (%) Metoprolol 53 39.25 Atenolol 38 28.14 Carvedilol 25 18.51 Propranolol 18 13.33 Labetolol 1 0.74

Page2590 CONCURRENT ANTI HYPERTENSIVE DRUGS PRESCRIBED The major anti-hypertensive drugs prescribed along with beta blockers were diuretics (51.11%), calcium channel blockers (38.5%) followed by angiotensin receptor blockers (22.2%) and angiotensin converting enzyme inhibitors (19.2%). Table 7: Concurrent anti-hypertensive Drugs Prescribed in the Study Population. ANTI HYPERTENSIVE DRUG NO. OF PATIENTS PERCENTAGE (%) Diuretics 69 51.11 Calcium channel blockers 52 38.5 Angiotensin receptor blockers 30 22.2 Angiotensin converting enzyme inhibitors (ACEI s) 26 19.2 Doses of Individual beta blockers Atenolol: Out of 135 patients, atenolol 50mg was prescribed for 21.4% of study population and 25mg was prescribed for 6.6% of study population. Table 8: Prescribed doses of Atenolol in the study population. Dose prescribed No. of patients Percentage (%) 25mg 9 6.6 50mg 29 21.4 Metoprolol: Out of 135 patients, Metoprolol 25mg was prescribed for 22.9% of study population, 8.1% of patients were prescribed. with 12.5mg and 50mg. Table 9: Prescribed doses of Metoprolol in the study population. Dose prescribed No. of patients Percentage (%) 12.5mg 11 8.1 25mg 31 22.9 50mg 11 8.1 Carvedilol: Out of 135 patients, carvedilol 3.125mg was prescribed for 16.2% of study population, 10mg was prescribed for 7.4% and 0.7% of patients were prescribed with 6.25mg. Table 10: Prescribed doses of Carvedilol in the study population. Dose prescribed No. of Patients Percentage (%) 3.125mg 22 16.2 6.25mg 1 0.7 10mg 2 7.4 Propranolol: Propranolol 40mg Out of 135 patients propranolol 10mg was prescribed for 5.9% of study population, 20mg for 4.4% and 2.9% were prescribed with 40mg. Table 11: Prescribed doses of Propranolol in the study population. Dose prescribed No. of patients Percentage (%) 10mg 8 5.9 20mg 6 4.4 40mg 4 2.9

Page2591 DRUG COMBINATIONS: Out of 135 study population 18 patients were prescribed with beta blocker (atenolol) in combination with calcium channel blocker (amlodipine). In 18 patients 7.4% were prescribed with Amlo-AT and 5.69% were prescribed with Stamlo beta. Table 12: Drug combinations prescribed in the study population. Brand prescribed No. of patients Percentage (%) Stamlo beta 8 5.9 Amlo AT 10 7.4 DRUG INTERACTIONS In the study population total 122 drug interaction were reported out of these 12 (9.83%) were major drug interactions whereas 110 (90.16%) were moderate. Table 13: Type of drug interactions noted in the study population. TYPE OF NO. OF PERCENTAGE (%) INTERACTION INTERACTIONS Major 12 9.83% Moderate 110 90.16% DISCUSSION: In our study, a total of 135 prescriptions were recorded from General medicine, General surgery, and ICU departments. Out of them, male patients were 66 (48.88%) and female were 69 (51.11%) as shown in Tab: 1. these findings are similar to study of Queen Mary Utilization of Antihypertensive Drugs Study (QUADS) conducted in 2004 observed 48% male and 52% female in the study [7]. Most common age group involved in our study was 50-69 years (50.3%), followed by 31-49 years (31.9%) and 70-90years (14.8%). In the present study prescribing pattern is extended for the duration of hospital stay and days of treatment. The duration of hospital stay is 37.7% for more than 7days (Shown in Table: 3). Prolonging the duration of hospital stay does not provide for an additional therapeutic benefit, and it may result in costly remedial care and adverse effect simultaneously. The chief complaints of admission include breathlessness (42.9%), swelling (29.6%), followed by generalized weakness and chest pain (17.7%) as shown in Table: 4. Major diagnosis in the study population included Hypertension (62.2%) followed by Diabetes mellitus (34.81%) and chronic heart failure (14.8%) as shown in Table: 6. Monitoring of blood pressure and daily weight records were obtained during hospitalization. In the present study it was observed that most commonly prescribed beta-blockers were Metoprolol (22.2%), Atenolol(21.4%), followed by vasodilator Carvedilol (16.2%) and propranolol (13.3%) in different dosages. Most of the beta blockers were prescribed in single formulation rather than two formulations like amlodipine plus atenolol (13.33%). Concomitant antihypertensive drugs prescribed other than beta blockers include diuretics (51.11%), calcium channel blockers (38.5%), angiotensin receptor blockers (22.2%) followed by angiotensin converting enzyme inhibitors (19.2%). Two d r u g r e g i m e n of diuretics and monotherapy of remaining anti hypertensives were prescribed. In the two drug combination, a beta blocker (atenolol) with calcium channel blocker (amlodipine) was often prescribed which was comparable with other study by H Tiwari et al [8]. In this form of combination beta blockers trend to blunt the troublesome reflex tachycardia induced by dihydropyridine class of CCB s. Earlier studies suggested that an ideal combination therapy must include anti-hypertensive drugs possessing complementary modes of action (synergistic effect) without any adverse effect with low dose. In majority of the patients the use of polypharmacy was reported to control or manage medical conditions. Therefore before prescribing a medication it is important to determine if the patient s condition is caused by a current medication. In the study population drug interactions were reported with major DI (9.83%) and moderate (90.16%). The most common interactions included among beta blockers with other anti hypertensives, also with anti-diabetics. CONCLUSION From this female dominated study it was concluded that beta blockers most commonly prescribed include Metoprolol followed by atenolol. It is highly necessary for the clinical pharmacist to review and clinically check all prescriptions presented at the wards (check for appropriate dose, frequency, drug interactions etc.). She/he should compulsory monitor the patient regarding medication adherence, so that the best choice of drug can be prescribed. A therapeutic audit provides regular feedback associated with the drug use with continuous education and training program. From the study it was concluded that most of the prescription were rational, but further improvement is needed. A therapeutic audit provides regular feedback associated with the drug use with continuous education and training programs among the health care team helps to improve the quality of patient care, in achieving National goal of pharmacoeconomics. In the future perspective, it is essential to identify if the usage is as per the guidelines and report to the health care authorities in promoting the rational use of beta blockers based on standard therapeutic guidelines.

Page2592 ACKNOWLEDGEMENT: I thank my Parents who have been the emblem of love and for their encouragement. It is with their support and guidance, I walk through the path of success. REFERENCES: 1. Swamy RM, Venkatesh G, Nagaraj HK, A prospective drug utilization evaluation of analgesics and pain assessment in postoperative urological patients in a Tertiary care hospital. Biomedical Research 2010; 21(4): 401-405. 2. Lemecha Diriba, Fikru Worku, Tsinuel Girma. Evaluation of prophylactic use of cotromoxazole for people living with HIV/AIDS in Jimma University specialized hospital, Southwest Ethiopia. Ethiop J Health Sciences 2008; 18(3):59-64. 3. APhA special report. Opportunities for the clinical pharmacist in managed care. Washington: American Pharmaceutical Association. 1994. 4. Simon F. Shakar, et al. Combined Oral Positive Inotropic and Beta-Blocker Therapy for treatment of Refractory Class-4 Heart Failure. JACC 1998; Vol 31, No.6:1336-40. 5. Khawaja Tahir Mehmood, et al. Rational U s e of Beta B l o c k e r s in M a n a g e m e n t Of Hypertension. JPSR 2011; 3(1); 1029-1034. 6. Dransfield M.T, et al. Use of Beta-blockers and the risk of death in hospitalized patients with acute exacerbations of COPD. BMJ 2008; 63:301-305. 7. Ali Ahmed et al. Beta-blockers in older patients with heart failure and preserved ejection fraction: Class, dosage, and outcomes. International Journal of Cardiology 2014; Vol-173: 393-401. 8. Tiwari H et al. Prescription monitoring of anti- hypertensive drug utilization at the Punjab university health centre in India. Singapore Medical Journal 2004; 45(3): 117-120. 54878478451150440